✅ Model Answer:
• Diagnosis: Central Diabetes Insipidus (ADH deficiency) – hypernatremia (156 mEq/L), elevated serum osmolality (315 mOsm/kg), dilute urine (180 mOsm/kg), normal glucose (excludes DM). Water deprivation test shows no concentration (urine osm remains 200 after 6 hours). DDAVP (desmopressin) causes a >50% rise in urine osmolality (from 200 to 620), confirming central DI.
• Any other test: MRI brain (pituitary/hypothalamus) to rule out tumor (craniopharyngioma, germinoma), histiocytosis, or structural lesion. Copeptin level (low in central DI). Autoantibodies (if autoimmune etiology suspected).
• What to do next: Start desmopressin (DDAVP) – intranasal (10-20 mcg/day) or oral (0.05-0.2 mg/day) or sublingual. Monitor serum sodium and urine output. Educate on signs of hyponatremia (over-treatment).
• Follow-up plan: Monitor sodium, urine output, weight. Adjust DDAVP dose to maintain normal sodium. Annual MRI if lesion found. Counsel on risk of hyponatremia. Regular endocrinology follow-up.

✅ Model Answer:
• Central Diabetes Insipidus (CDI) is a disorder characterized by deficiency of antidiuretic hormone (ADH/vasopressin) from the posterior pituitary, leading to polyuria, polydipsia, and dilute urine.
• Causes:
- Idiopathic: Most common (autoimmune destruction of ADH-producing neurons).
- Brain tumors: Craniopharyngioma, germinoma, pituitary adenoma, glioma (especially in children).
- Histiocytosis: Langerhans cell histiocytosis (LCH).
- Head trauma: Skull fracture, surgery.
- Infections: Meningitis, encephalitis, tuberculosis.
- Genetic: Autosomal dominant (AVP gene mutations), autosomal recessive (Wolfram syndrome — DIDMOAD: Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, Deafness).
- Autoimmune: Associated with type 1 diabetes, autoimmune thyroiditis.
- Hypothalamic/pituitary lesions: Craniopharyngioma is the most common tumor causing CDI in children.

✅ Model Answer:
• Water deprivation test is the gold standard for diagnosing diabetes insipidus and differentiating central from nephrogenic DI.
• Procedure:
- Withhold fluids for 4-6 hours (or until 3% weight loss).
- Monitor: Serum sodium, serum osmolality, urine osmolality, weight hourly.
- Stop if: Serum Na >150 mEq/L, serum osmolality >300 mOsm/kg, or 3% weight loss.
- Then give DDAVP (desmopressin) 2-4 mcg SC or 10 mcg intranasal.
- Measure urine osmolality 1-2 hours after DDAVP.
• Interpretation:
- Central DI: Urine osm remains <300 during dehydration, rises >50% (or >600) after DDAVP.
- Nephrogenic DI: Urine osm remains <300 during dehydration, <50% rise (or <600) after DDAVP.
- Primary polydipsia: Urine osm rises to >800 during dehydration (normal ADH response).

✅ Model Answer:
• Copeptin: A 39-amino acid glycopeptide derived from the same precursor as ADH (vasopressin).
• Role: Copeptin is a surrogate marker for ADH secretion.
• Advantages over direct ADH measurement:
- ADH has a very short half-life (5-10 minutes) and is unstable in vitro.
- Copeptin is stable at room temperature for several days.
- Copeptin levels correlate well with ADH.
• Interpretation:
- Central DI: Low copeptin (<2 pmol/L) during hypertonic stimulation (water deprivation).
- Nephrogenic DI: High copeptin (>5 pmol/L) despite dilute urine.
- Primary polydipsia: Normal copeptin response.
• Clinical use: Increasingly used as a less invasive alternative to water deprivation testing.

✅ Model Answer:
• Desmopressin (DDAVP): Synthetic analogue of ADH — the mainstay of treatment.
- Routes: Intranasal (10-20 mcg/day), oral (0.05-0.2 mg/day), sublingual, or SC.
- Dosing: Start low, titrate based on urine output and serum sodium.
- Goal: Maintain normal sodium and reduce polyuria to 1-2 L/day.
• Monitoring:
- Serum sodium: Monitor weekly initially, then monthly once stable.
- Urine output: Target 1-2 mL/kg/h.
- Weight: Daily weight to detect fluid overload.
• Complications:
- Hyponatremia: Most common complication (over-treatment).
- Water intoxication: If DDAVP dose is too high or fluid intake is excessive.
- Risk factors: Intercurrent illness, hot weather, psychogenic polydipsia.

✅ Model Answer:
• Complications:
- Hypernatremia: Severe dehydration, hyperosmolar state → confusion, seizures, coma, death.
- Hyperosmolar dehydration: Weight loss, dry mucous membranes, tachycardia, hypotension.
- Hypovolemia: Decreased urine output (if severe dehydration).
- Electrolyte disturbances: Hypernatremia, hyperchloremia.
- Cerebral edema: If sodium is corrected too rapidly.
- Growth failure: Due to chronic dehydration and poor appetite.
- Nocturia: Sleep disturbance, fatigue.
- Psychosocial: Impact on school, social activities (frequent trips to the bathroom).
- Underlying cause: If tumor, may cause other pituitary hormone deficiencies (hypopituitarism) or visual field defects.

✅ Model Answer:
• MRI Brain (pituitary/hypothalamus): Essential in the evaluation of central DI.
• Findings:
- Normal: Absence of posterior pituitary bright spot (loss of ADH signal) — seen in 50-70% of CDI.
- Tumor: Craniopharyngioma (suprasellar mass, calcifications), germinoma (pituitary stalk thickening), glioma.
- Histiocytosis: Hypothalamic or pituitary stalk thickening.
- Inflammatory: Hypophysitis (pituitary enhancement).
- Post-traumatic: Pituitary stalk transection.
• Indications: All children with central DI should have a high-resolution MRI with contrast.
• Follow-up: If a lesion is found, repeat MRI every 6-12 months to monitor progression. If no lesion found, repeat MRI every 1-2 years (risk of delayed tumor presentation).

✅ Model Answer:
• Prognosis:
- Good: With appropriate DDAVP therapy, most children lead normal lives.
- If underlying tumor: Prognosis depends on the tumor type and resectability.
- Idiopathic: May be lifelong but well-controlled with DDAVP.
- Autoimmune: May be associated with other autoimmune diseases (type 1 diabetes, thyroiditis).
- Life expectancy: Normal if treated and monitored appropriately.
• Long-term follow-up:
- Endocrinology: Regular follow-up for DDAVP dose adjustment, sodium monitoring.
- MRI: If no lesion found, repeat MRI every 1-2 years to rule out delayed tumor.
- Growth and development: Monitor for other pituitary hormone deficiencies (GH, TSH, ACTH, gonadotropins).
- Education: Teach child and family about signs of hyponatremia (headache, nausea, confusion) and hypernatremia (thirst, dry mouth).
- Emergency plan: Sick day rules (DDAVP may need to be held if vomiting/hyponatremia).